Drug | cLogD | tPSA | Metabolite | pKa | cLogD | tPSA | M/P | Conjugate | fm | Ref |
---|---|---|---|---|---|---|---|---|---|---|
Amiodarone | 5.87 | 42.7 | 3′-OH-desethyl amiodarone | 14.97 | 3.69 | 71.7 | 0.39 | McDonald et al., 2012 | ||
Bosentan | 2.36 | 154 | Hydroxybosentan | 14.63 | 0.65 | 174 | 0.11–0.13 | 0.3 | Weber et al., 1999; van Giersbergen et al., 2002 | |
Bromhexine | 3.69 | 29.3 | Hydroxybromhexine | 15.11 | 2.38 | 49.5 | E4-OH:0.42; E3-OH:0.17 | Liu et al., 2010 | ||
Bufuralol | 1.46 | 45.4 | 1′-Hydroxybufuralol | 14.3 | 0.066 | 65.6 | 1 | Pringle et al., 1986 | ||
Bupropion | 2.13 | 29.1 | Hydroxybupropion | 15.43 | 1.28 | 49.3 | 7 to 41 | Kirchheiner et al., 2003a; Loboz et al., 2006 | ||
Dihydrobupropion | 13.67 | 0.94 | 32.1 | Threo: 6.4; Erthro:1.8 | Yeung et al., 2011 | |||||
Buspirone | 1.24 | 69.6 | Hydroxybuspirone | 12.5 | −0.4 | 89.9 | 34–44 | Jajoo et al., 1989; Dockens et al., 2006 | ||
Celecoxib | 2.59 | 83.4 | Hydroxycelecoxib | 14.16 | 0.93 | 107 | 0.05 | 0.73 | Paulson et al., 2000; Kirchheiner et al., 2003b | |
Cerivastatin | 0.071 | 99.9 | Hydroxycerivastatin | 14.4 | −1.36 | 120 | 0.24–0.37 | Muck, 2000 | ||
O-Desmethyl cerivastatin | 13.38 | −0.7 | 111 | 0.08–0.11 | ||||||
Clarithromycin | 2.06 | 183 | Hydroxyclarithromycin | 14.1 | 0.99 | 203 | 0.67 (SD); 0.42 (MD) | 0.2 | Ferrero et al., 1990; Cheng et al., 1998 | |
Dolansetron | 2.54 | 62.4 | Dehydrodolasetron | 14.59 | 1.23 | 65.6 | >1 | 0.32 | Reith et al., 1995; Lerman et al., 1996 | |
Darifenacin | 1.95 | 55.6 | Hydroxydarifenacin | 13.52 | 0.86 | 75.6 | 1–1.3 | 0.32 | Beaumont et al., 1998; Skerjanec, 2006 | |
Erlotinib | 3 | 74.7 | Desmethylerlotinib | 13.9 | 2.41 | 85.7 | 0.05 | 0.04 | Frohna et al., 2006; Ling et al., 2006 | |
Flutamide | 3.52 | 74.9 | Hydroxyflutamide | 12.87 | 2.67 | 95.2 | 73 | Anjum et al., 1999 | ||
Indacaterol | 2.33 | 61.4 | Hydroxyindacaterol | 14.58 | 0.39 | 81.6 | 0.39 | 0.2 | Kagan et al., 2012 | |
Haloperidol | 2.93 | 40.5 | Dihydrohaloperidol | 14.29 | 1.56 | 43.7 | 0.88 | Chakraborty et al., 1989 | ||
Itraconazole | 4.93 | 102 | Hydroxyitraconazole | 14.98 | 3.46 | 121 | 1.4 | Templeton et al., 2008 | ||
Ketanserine | 3.05 | 69.7 | Ketanserinol | 14.06 | 2.07 | 72.9 | 3.2–3.5 | Lebrec et al., 1990 | ||
Metoprolol | −0.47 | 50.7 | α-Hydroxymetoprolol | 13.74 | −1.68 | 70.6 | 0.56 | Cerqueira et al., 2005 | ||
O-Desmethylmetoprolol | 14.9 | −1.09 | 61.7 | ND | ||||||
Midazolam | 3.78 | 30.2 | 1’-Hydroxymidozalam | 13.59 | 2.5 | 50.4 | 0.48 | Yes | 0.65 | Heizmann and Ziegler, 1981; Eap et al., 2004 |
Montelukast | 3.2 | 95.7 | Hydroxymontelukast (M1) | 15.86 | 2.2 | 116 | 0.06 | Karonen et al., 2012 | ||
Hydroxymontelukast (M5a/5b) | 13.98 | 1.82 | 116 | 0.77 | ||||||
Nalidixic acid | −1.54 | 70.5 | Hydroxynalidixic acid | 13.02 | −2.3 | 90.7 | 0.69 | Cuisinaud et al., 1982 | ||
Naltrexone | 1.6 | 70 | 6-β-Naltrexol | 14.42 | 0.24 | 73 | 29 | Yun et al., 2007 | ||
Nebivolol | 2.75 | 70.6 | Hydroxynebivolol | 13.98 | 1.23 | 91.2 | 21 | Kamali et al., 1997 | ||
Nefazadone | 3.89 | 51.6 | Hydroxynefazadone | 13.8 | 3.55 | 71.9 | 0.35–0.55 | Barbhaiya et al., 1995,1996a,b | ||
Nelfinavir | 7.26 | 127 | Hydroxynelfinavir | 16.11 | 6.1 | 147 | 0.37 | Zhang et al., 2001 | ||
Nortryptyline | 1.49 | 12 | Hydroxynortryptyline | 13.9 | −0.25 | 32.3 | 0.36–13 | Dalen et al., 1998 | ||
Omeprazole | 2.35 | 96.3 | Hydroxyomeprazole | 13.15 | 1.2 | 117 | 0.42 to 0.7 | 0.25 | Renberg et al., 1989; Andersson et al., 1990; Lutz and Isoherranen, 2012 | |
Pagoclone | 3.31 | 65.2 | Hydroxypagoclone | 14.98 | 1.64 | 83.4 | 65% of total plasma radioactivity | Dalvie et al., 2009 | ||
Pioglitazone | 2.45 | 93.6 | Hydroxypioglitazone | 13.74 | 0.89 | 114 | SD: 3.8; MD:1.8 | Eckland and Danhof, 2000; Budde et al., 2003 | ||
Praziquantel | 2.66 | 40.6 | Hydroxypraziquantel | 15.02 | 1.02 | 60.9 | (+)S:9.0; (−)R: 33-38 | Westhoff and Blaschke, 1992; Lima et al., 2009 | ||
Quinidine | 0.98 | 45.6 | Hydroxyquinidine | 13.93 | 0.88 | 65.8 | 0.26 to 0.29 | Rakhit et al., 1984; Schellens et al., 1991 | ||
Repaglinide | 1.99 | 78.9 | Hydroxyrepaglinide | 14.79 | 0.42 | 99.1 | 0.02* | 0.01 | van Heiningen et al., 1999; Honkalammi et al., 2011 | |
Risperidone | 1.89 | 61.9 | Hydroxyrisperidone | 13 | 0.61 | 82.2 | 3 to 6 | 0.25 | Mannens et al., 1993; Zhou et al., 2006; Mahatthanatrakul et al., 2012 | |
Ruzolitinib | 2.07 | 83.2 | Hydroxyruzolitinib | 14.94 | 0.56 | 103 | 0.24 to 0.3 | 0.05 | Shilling et al., 2010; Shi et al., 2012 | |
Taranabant | 6.29 | 75 | Hydroxytaranabant | 15.14 | 5.58 | 95.2 | 2.5 to 3.3 | Addy et al., 2008; Karanam et al., 2010 | ||
Terfenadine | 3.6 | 43.7 | Hydroxyterfenadine | 14.96 | 1.88 | 63.9 | ND | Abernethy et al., 2001 | ||
Tibolone | 3.52 | 37.3 | 3α-Hydroxytibolone | 15 | 3.96 | 40.5 | 0.44 | 0.16 | Vos et al., 2002 | |
Ticagrelor | 2.02 | 164 | O-Desalkylticagrelor | 14.28 | 2.02 | 155 | 0.4 | 0.22 | Teng et al., 2010 | |
Tolterodine | 2.37 | 23.5 | Hydroxytolteridine | 14.71 | 1.93 | 43.7 | 0.82 | Brynne et al., 1999 | ||
Valdecoxib | 3.56 | 94.6 | Hydroxyvaldecoxib | 13.09 | 2.36 | 115 | 0.08 to 0.1 | Yes | 0.23 | Yuan et al., 2002; Sarapa et al., 2005 |
* Denotes M/P ratio from single time point concentration.